CA received travel grants and honoraria from Gilead, ViiV Healthcare, MSD, Janssen. DR is member of editorial board (past) for Gilead and received meeting expenses from BMS, Gilead, MSD, ViiV, Janssen. CD has received travel grants, honoraria or study grants from Abbvie, Bristol-Myers-Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare. JR reports grants and personal fees from Gilead, Janssen, MSD, ViiV Healthcare. TM received travel grants or honoraria from VIIV, BMS, MSD, Janssen. FR received research funding or honoraria or consulted for Abbvie, BMS, Gilead, Janssen, and MSD, MH, FBS, AGB, CJ, IPM, PP, AC, PD, CK, VJ, ChC, BH, DM, TM, AGB, CCh, TH have no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.